MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/icb.0000000000000675

Медицинская библиотека · Retinal cases & brief reports · 2020

IMMUNE RETINOPATHY ASSOCIATED WITH NIVOLUMAB ADMINISTRATION FOR METASTATIC NON-SMALL CELL LUNG CANCER.

Reddy Manisha, Chen Judy J, Kalevar Ananda, Terribilini Ryan, Agarwal Anita

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: To present a novel case of immune retinopathy associated with nivolumab therapy for non-small cell lung cancer.

METHODS

Retrospective chart review.

RESULTS

A 64-year-old woman presented with photoreceptor injury evidenced by hypoautofluorescent and hyperautofluorescent patches on fundus autofluorescence, loss of the ellipsoid zone on optical coherence tomography, and dysfunction of the rods and cones on electroretinogram. She had a history of Stage IV lung adenocarcinoma, treated with nivolumab, a checkpoint inhibitor. Serology testing was negative for paraneoplastic antibody panel, antirecoverin and antienolase antibodies, but positive for antiretinal antibodies against 30-kDa (carbonic anhydrase II), 35-kDa (GADPH), 38-kDA, 58-kDa (PKM2), and 112-kDa proteins. Cessation of the medication and high-dose oral steroids resulted in resolution of her symptoms and stability of ocular findings.

CONCLUSION

The checkpoint inhibitors, including nivolumab, have significant ocular side effects. All patients receiving nivolumab should undergo a baseline comprehensive eye examination and should be counseled to seek medical attention immediately if visual changes occur.

Для цитирования: Reddy Manisha, Chen Judy J, Kalevar Ananda, Terribilini Ryan, Agarwal Anita. IMMUNE RETINOPATHY ASSOCIATED WITH NIVOLUMAB ADMINISTRATION FOR METASTATIC NON-SMALL CELL LUNG CANCER.. Retinal cases & brief reports. 2020. DOI: 10.1097/icb.0000000000000675.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.